INTRODUCTION {#sec1-1}
============

Infection with *Leishmania* species can lead to various clinical presentations, such as cutaneous, mucocutaneous, and visceral leishmaniasis (VL).\[[@ref1]\] The VL form, the most and lethal, is also known as Kala Azar.\[[@ref2]\] Previous research has shown that VL patients suffer from an impaired immune response against *Leishmania* parasites; hence, the parasite cannot be cleared completely.\[[@ref3]\] Interleukin 4 (IL-4) is a cytokine that is, produced by Th2 lymphocytes and plays key roles in the induction of a humoral immune response, including isotype switching to IgE.\[[@ref4]\] Additionally, IL-4, as a Th2 cytokine, suppresses the Th1 responses that are crucial for the elimination of intracellular pathogens such as *Leishmania*.\[[@ref5][@ref6]\] Therefore, sufficient, but not excess, production of IL-4 leads to appropriate immune responses to parasites.\[[@ref7][@ref8]\] Previous studies have shown that IL-4 is significantly upregulated in leishmaniasis,\[[@ref9][@ref10]\] indicating that this cytokine plays a key role in the induction of immune responses against *Leishmania*. IL-4 performs its function by attaching to its corresponding receptor (IL-4R) through a JAK/STAT signaling pathway, suggesting that polymorphisms altering IL-4R expression can alter the outcome of *Leishmania* infection. Single nucleotide polymorphisms at positions 1432 (T1432C) and 1652 (A1652G) of the IL-4Rα gene have been associated with altered IL-4Rα expression.\[[@ref11]\] Therefore, these polymorphisms may be associated with impaired immune responses against *Leishmania* in VL. Thus, this study was designed to evaluate the IL-4Rα T1432C and A1652G polymorphisms in seropositive VL patients compared to healthy controls with and without anti-*Leishmania* antibodies in a selected Iranian population.

MATERIALS AND METHODS {#sec1-2}
=====================

Subjects {#sec2-1}
--------

This cross-sectional study was performed during 2004--2012. IL-4Rα T1432C and A1652G genotyping were evaluated in 124 VL patients (Group 1) with mean age of 19.1 ± 14.2 years, 101 seropositive healthy controls (Group 2) with mean age of 25.7 ± 18.03 years, and 55 seronegative healthy controls (Group 3) with mean age of 21.5 ± 14.0 years. The control subjects were matched regarding age, nationality, and race. All study subjects were from three close cities (Kelybar, Ahar and Mianeh) in East-Azerbaijan province, North-West of Iran, which is an endemic region for *Leishmania* infantum.\[[@ref12][@ref13][@ref14]\] Also, the sex ratios (female/male) were 58/66 in Group 1, 48/53 in Group 2 and 29/26 in healthy controls, respectively.

VL was diagnosed in participants by a specialist, based on clinical presentations, laboratory findings, and medical history. The signs and symptoms of VL were fever, severe anemia, weakness, cough, diarrhea, vomiting, fatigue, and appetite loss. The Ethical Committee of the Hamadan University of Medical Sciences approved the study protocol and written informed consent was obtained from all participants prior to sample collection.

DNA extraction {#sec2-2}
--------------

Ten milliliters of venous blood were collected from each subject into tubes containing 50 mmol/L ethylenediaminetetraacetic acid, and genomic DNA was isolated from anti-coagulated peripheral blood buffy coat using Miller\'s salting-out method. All samples from cases and controls were handled in identical fashion as previously described.\[[@ref15]\]

Polymorphism detection {#sec2-3}
----------------------

IL-4Rα polymorphisms T1432C and A1652G were evaluated using a polymerase chain reaction (PCR)-restriction fragment length polymorphism technique that has been described elsewhere.\[[@ref11]\] Briefly, the amplification reactions were performed in a volume of 20 microliters containing 50 ng of genomic DNA, ×1 PCR buffer, 1.5 mM MgCl~2~, 0.5U Taq DNA polymerase (Roche, Germany) and allele-specific primers,\[[@ref11]\] using thermocycler (PEQLab, Germany). However, the restriction enzymes for genotyping were used as follows; BseRI and AvaI for IL-4Rα T1432C and AvaI for A1652G genotypes, respectively.

Immunoflorescence assay {#sec2-4}
-----------------------

Anti-*Leishmania* antibody was detected and titred using a IFA *Leishmania* commercial kit (Euroimmun, Germany) according to the manufacturer\'s guidelines. In brief, double fold dilutions of patients' sera (from 1/10 to 1/320) were tested against commercial parasite coated slides in the presence of negative and positive controls. The observation of fluorescence in samples with dilution over 1/160 was considered as positive.

Statistical analysis {#sec2-5}
--------------------

Hardy--Weinberg equilibrium analysis was used to validate the raw data. The *χ*^2^ and one-way tests were performed using SPSS (SPSS Inc., Chicago, IL, USA) to determine the differences in polymorphism prevalence between groups. *P* \<0.05 was considered significant.

RESULTS {#sec1-3}
=======

Participant groups showed a significant difference in IL-4Rα genotypes at the two positions so that, high frequencies of IL-4Rα 1432 TT and 1652 AA genotypes were observed among VL patients compared to healthy controls (*P* = 0.026 and *P* \< 0.001, respectively), \[[Table 1](#T1){ref-type="table"}\]. Also, higher significant frequency of IL-4Rα 1652 A allele was found among VL patients versus controls (*P* = 0.003), \[[Table 1](#T1){ref-type="table"}\].

###### 

The prevalence of IL-4Rα T1432C and A1652G genotypes and alleles among seropositive VL patients (group 1) and seropositive and seronegative healthy controls (group 2 and 3)
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These results also revealed that anti-*Leishmania* antibody titers did not differ significantly between participants in Group 1 (*P* = 0.251) and Group 2 (*P* = 0.769) with various IL-4Rα T1432C genotypes, or between participants in Group 1 (*P* = 0.077) and Group 2 (*P* = 0.116) with various IL-4Rα A1652G genotypes \[[Table 2](#T2){ref-type="table"}\].

###### 

The titration of anti-leishmania antibody in group 1 and 2 carrying various IL-4Rα T1432C and A1652G genotypes
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DISCUSSION {#sec1-4}
==========

IL-4 is released by many immune cells, including Th2 lymphocytes and mast cells. Up-regulation of IL-4 during parasitic infections leads to IgE production by B lymphocytes and also the development of mast cells, eosinophils, and basophils that are important in combating parasites such as leishmaniasis.\[[@ref11]\] Conversely, ectopic expression of IL-4 results in immune responses toward Th2 profile which has been reported in VL cases.\[[@ref3][@ref16]\] Because IL-4 functions via interaction with a corresponding receptor (IL-4R),\[[@ref11]\] genetic and epigenetic changes that alter IL-4R expression can lead to alterations in the immune response to *Leishmania*. Previous studies have shown that expression of IL-4R is modulated by polymorphisms within the IL-4Rα gene.\[[@ref11]\] Our results revealed that the IL-4Rα 1432 T/T genotype and the IL-4Rα 1652 A/A genotypes were significantly associated with VL in these Iranian patients. VL patients are unable to eradicate the parasite from the body.\[[@ref3]\] So, it may be concluded that IL-4Rα 1652 A/A genotypes, A allele and also IL-4Rα 1432 T/T genotype, which were more prevalent in Group 1, may be associated with an impaired immune responses against *Leishmania*.\[[@ref3]\] Additionally, it has been reported that serum levels of IL-4 are significantly elevated in VL patients in comparison to healthy controls.\[[@ref17][@ref18]\] Therefore, it is speculated that although IL-4 production is necessary in VL patients, impaired expression of IL-4R, possibly related to the polymorphisms evaluated in this study, results in reduced IL-4 function against VL. To our knowledge, this is the first study that has shown as the association between IL-4Rα polymorphisms at positions T1432C and A1652G and VL disease. However, previous studies have examined the association of distinct polymorphisms within the IL-4 gene and VL disease. For instance, polymorphisms within intron 2 and 3 of IL-4 (IL4RP1 and 2) have been associated with VL.\[[@ref19]\] Interestingly, polymorphisms within the IL-4 gene have also been found to be associated with other parasitic infections, such as *Plasmodium falciparum*.\[[@ref20][@ref21]\] and *Trypanosoma cruzi*.\[[@ref22]\] Our results support the view that IL-4 polymorphisms are an important genetic risk factor for the development of VL. Our results also revealed that VL patients and seropositive healthy controls with various statuses of IL-4Rα T1432C and A1652G genotype and alleles did not differ in the titers of anti-*Leishmania* antibody. Therefore, it may be concluded that the genotypes we examined did not alter humoral immunity against leishmaniasis.

CONCLUSION {#sec1-5}
==========

Our findings indicate that the IL-4Rα gene polymorphisms at two positions T1432C and A1652G could be considered as possible genetic risk factors in the immunopathogenesis of VL disease in Iranian patients. Although, further studies on larger groups of patients and evaluation of IL-4R at protein levels are needed to clarify the exact role of this molecule in susceptibility and/or immunopathogenesis of visceral leishmaniasis.
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